Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [8]
- Comments [0]
- Validations
- Western blot [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 10051-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#10051-1-AP, RRID:AB_2220309
- Product name
- BCRP/ABCG2 antibody
- Antibody type
- Polyclonal
- Description
- BCRP/ABCG2 antibody (Cat. #10051-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Interferon regulatory factor-1 reverses chemoresistance by downregulating the expression of P-glycoprotein in gastric cancer.
MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.
Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.
Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.
Yuan J, Yin Z, Tan L, Zhu W, Tao K, Wang G, Shi W, Gao J
Cancer letters 2019 Aug 10;457:28-39
Cancer letters 2019 Aug 10;457:28-39
MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M, Fu Z, Cao J, Liu Y, Wu J, Li Q, Chen Y
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018 Jun;102:286-294
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018 Jun;102:286-294
Low-density lipoprotein-coupled micelles with reduction and pH dual sensitivity for intelligent co-delivery of paclitaxel and siRNA to breast tumor.
Zhu WJ, Yang SD, Qu CX, Zhu QL, Chen WL, Li F, Yuan ZQ, Liu Y, You BG, Zhang XN
International journal of nanomedicine 2017;12:3375-3393
International journal of nanomedicine 2017;12:3375-3393
Knockdown of SALL4 expression using RNA interference induces cell cycle arrest, enhances early apoptosis, inhibits invasion and increases chemosensitivity to temozolomide in U251 glioma cells.
Zhang L, Yan Y, Jiang Y, Qian J, Jiang L, Hu G, Lu Y, Luo C
Oncology letters 2017 Oct;14(4):4263-4269
Oncology letters 2017 Oct;14(4):4263-4269
Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target.
Xie P, Yang JP, Cao Y, Peng LX, Zheng LS, Sun R, Meng DF, Wang MY, Mei Y, Qiang YY, Cao L, Xiang YQ, Luo DH, Yun JP, Huang BJ, Jia LJ, Qian CN
Cell death & disease 2017 Jun 1;8(6):e2834
Cell death & disease 2017 Jun 1;8(6):e2834
Involvement of protoporphyrin IX accumulation in the pathogenesis of isoniazid/rifampicin-induced liver injury: the prevention of curcumin.
He L, Guo Y, Deng Y, Li C, Zuo C, Peng W
Xenobiotica; the fate of foreign compounds in biological systems 2017 Feb;47(2):154-163
Xenobiotica; the fate of foreign compounds in biological systems 2017 Feb;47(2):154-163
PET study on mice bearing human colon adenocarcinoma cells using [11C]GF120918, a dual radioligand for P-glycoprotein and breast cancer resistance protein.
Yamasaki T, Kawamura K, Hatori A, Yui J, Yanamoto K, Yoshida Y, Ogawa M, Nengaki N, Wakisaka H, Fukumura T, Zhang MR
Nuclear medicine communications 2010 Nov;31(11):985-93
Nuclear medicine communications 2010 Nov;31(11):985-93
Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.
Wang H, Lee EW, Cai X, Ni Z, Zhou L, Mao Q
Biochemistry 2008 Dec 30;47(52):13778-87
Biochemistry 2008 Dec 30;47(52):13778-87
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The BCRP/ABCG2 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human BCRP/ABCG2. This antibody recognizes human, mouse antigen. The BCRP/ABCG2 antibody has been validated for the following applications: ELISA, WB analysis.
